Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 670 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept Patient Guide in Testicular Cancer Now Available Also in German AI Model Identifies How Every Country Can Improve Its Cancer Outcomes MOST POPULAR Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma December 9, 2020 Pursuing precision medicine in a flagship lung cancer trial July 15, 2020 Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and... December 20, 2023 Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 Load more HOT NEWS Research with Integrity – the madness of short methods Atlantic rowing trio smash world record and raise thousands for cancer... EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab Summer Sun Safety Tips
